Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thenalidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thenalidine SCHEMBL4424748 | 0.90 | OPRM1 (0.80) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| SCHEMBL19557303 | 0.83 | CHRM2 (0.71) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| SCHEMBL6622324 | 0.83 | OPRM1 (0.70) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| Bamipine SCHEMBL29626 | 0.80 | KCNH2 (0.66) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| Bamipine SCHEMBL4424873 | 0.79 | KCNH2 (0.64) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| Bamipine SCHEMBL1649707 | 0.77 | KCNH2 (0.63) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| SCHEMBL17504857 | 0.76 | CHRM1 (0.61) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| Pyrilamine SCHEMBL28086129 | 0.75 | HRH1 (0.57) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| SCHEMBL19559069 | 0.75 | SLC6A2 (0.60) | OPRM1CHRM2CHRM1HTR1AADRA2A | |
| Bamipine SCHEMBL3217102 | 0.74 | OPRM1 (0.59) | OPRM1CHRM2CHRM1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856145-A1 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION (W/O) AND ITS USES | Galderma Research & Development (FR) | 2021-08-04 | — | — | EP | claimed |
| US-20210220269-A1 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION (W/O) AND ITS USES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2021-07-22 | — | — | US | claimed |
| WO-2020065085-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BRIMONIDINE, AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-04-02 | — | — | WO | claimed |
| WO-2020064843-A1 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION (W/O) AND ITS USES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-04-02 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2846809-A1 | TREATMENT OF MYELOSUPPRESSION | Cantex Pharmaceuticals, Inc. (US) | 2015-03-18 | — | — | EP | claimed |
| CN-104411316-A | Treatment of myelosuppression | PARINGENIX INC | 2015-03-11 | — | — | CN | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| WO-2013169355-A1 | TREATMENT OF MYELOSUPPRESSION | PARINGENIX, INC. (US) | 2013-11-14 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-6242509-B1 | ESTER-TERMINATED DIMER ACID-BASED POLYAMIDE AND FUNGICIDE, HEMORRHOID OR WART TREATMENT AGENT, ANTI-ITCHING AGENT, ANTIBIOTIC OR TOPICAL ANALGESIC; CANDLES | INTERNATIONAL PAPER COMPANY | 2001-06-05 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1027032-A1 | ESTER-TERMINATED POLYAMIDE GELS | UNION CAMP CORPORATION (US) | 2000-08-16 | — | — | EP | claimed |
| CN-1238678-A | Ester-terminated polyamide gels | UNION CAMP CORP (US) | 1999-12-15 | — | — | CN | claimed |
| CN-1204264-A | Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and kappa-2 opioid agonist | UNIV QUEENSLAND (AU) | 1999-01-06 | — | — | CN | claimed |
| CN-1195286-A | Epidural administration therapeutic compounds with sustained rate of release | DEPOTECH CORP (US) | 1998-10-07 | — | — | CN | claimed |
| WO-1998017243-A1 | ESTER-TERMINATED POLYAMIDE GELS | UNION CAMP CORPORATION (US) | 1998-04-30 | — | — | WO | claimed |
| US-5660839-A | CONSISTS OF AN OIL AND/OR WAX, AND A DEFOAMBLE HOLLOW PARTICULATE COMPRISING A TERPOLYMER OF ACRYLONITRILE-VINYLIDENE CHLORIDE AND A (METH) ACRYLATE; USED FOR TOPICAL APPLICATION TO HUMAN HAIR OR SKIN | L'OREAL (FR) | 1997-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220269-A1 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION (W/O) AND ITS USES | SQLE, LIPA, PLIN5 | OPRM1 640/4885CHRM2 1450/4885CHRM1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.